Windsor, Canada Clinical Trials

A listing of Windsor, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 870 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Henry Ford Hospital /ID# 162682
 (4.8 away) Contact site
  • 251 views
  • 29 Apr, 2021
  • +134 other locations
featured
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

antihypertensive drugs
antihypertensive therapy
angiography
hypertensive medication
hypertension
Henry Ford Hospital
 (4.0 away) Contact site
  • 877 views
  • 10 Jul, 2021
  • +82 other locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

metastatic cancer
FGFR2
primary cancer
cancer
Karmanos Cancer Institute
 (2.5 away) Contact site
  • 154 views
  • 14 Dec, 2020
  • +154 other locations
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

Henry Ford Hospital
 (4.0 away)
  • 261 views
  • 19 Jul, 2021
  • +64 other locations
featured
ECOSPOR III: A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults

ECOSPOR III is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in adult subjects 18 years of age or older with recurrent CDI, defined as: a history of ≥ 3 CDI episodes within 9 months, inclusive of the current …

antibiotic therapy
antibiotics
clostridium difficile
fidaxomicin
vancomycin
Henry Ford Health Hospital
 (4.8 away) Contact site
  • 1092 views
  • 21 Dec, 2020
  • +71 other locations
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …

Barbara Ann Karmanos Cancer Institute
 (2.5 away)
  • 1875 views
  • 26 Mar, 2021
  • +14 other locations
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …

Barbara Ann Karmanos Cancer Institute
 (2.5 away)
  • 268 views
  • 26 Mar, 2021
  • +15 other locations
featured
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

RADIANCE-II is a pivotal trial, currently enrolling patients, to study the safety and effectiveness of the Paradise System to reduce blood pressure in patients with hypertension, in the absence of antihypertensive medications. RADIANCE-II is currently enrolling patients with uncontrolled blood pressure on 0-2 medications.  

Henry Ford Hospital
 (4.8 away) Contact site
  • 315 views
  • 30 Mar, 2021
  • +20 other locations
featured
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

refractory follicular lymphoma
lymphoid malignancy
idelalisib
Barbara Ann Karmanos Cancer Institute
 (2.5 away) Contact site
  • 304 views
  • 23 Nov, 2020
  • +5 other locations
featured
[ONLINE] SPEECH BIOMARKERS: NEUROCOGNITIVE FUNCTIONING IN HEALTHY ADULTS

The Frontotemporal Degeneration Center and the Linguistic Data Consortium at the University of Pennsylvania are working to develop simple, easy, and effective ways to track neurocognitive health through short interactions with a web app. You can help us create a large open dataset, which researchers all over the world will …

Online11
 (1.4 away) Contact site
  • 635 views
  • 22 Oct, 2020
  • +251 other locations